Transoma wins FDA clearance for Sleuth AT cardiac monitoring system

The Sleuth products offer physicians the ability to diagnose patients with recurrent, unexplained fainting and abnormal heart rhythms quickly with its virtually unlimited memory capacity and hands-free downloading for the patient, while minimizing paperwork and practice workload, the company said.

With Sleuth AT, physicians can now choose to program the capture of high-quality electrocardiogram (ECG) strips at frequent intervals, providing a new level of insight into complex arrhythmias which are often asymptomatic and frequently changing.

Nestor Jaramillo, vice president of sales and marketing at Transoma, said: “We are pleased to announce FDA marketing clearance of the Sleuth AT system. We are experiencing great success with our first clinical product which was based on more than 20 years of experience with our remote, wireless monitoring technology platform in biomedical research.

“In addition to providing insight into the cause of unexplained, infrequent symptoms, Sleuth AT is designed to provide physicians with timely and accurate ECG data that could allow them to monitor the efficacy of prescribed therapies.”